
Cingulate (CING) Stock Forecast & Price Target
Cingulate (CING) Analyst Ratings
Bulls say
Cingulate is a clinical-stage biopharmaceutical company with a promising drug delivery platform technology for once-daily tablets and two first-line stimulant medications for the treatment of ADHD. The company has a positive outlook for potential FDA approval for CTx-1301 in mid-2026, with a large market potential for ADHD and a projected $18 billion in U.S. medication sales. Cingulate's commercial readiness initiatives and strategic partnerships position them for a rapid launch and potential growth, with potential risks including product efficacy and regulatory approvals.
Bears say
Cingulate is facing multiple risks such as balance sheet and liquidity concerns, potential failure of their product candidates in clinical trials, regulatory hurdles, and competition. While the usage of their PTR drug delivery platform for their ADHD medications may differentiate them, it remains to be seen if they will be able to successfully commercialize these products and obtain suitable reimbursement. Overall, there are many uncertainties surrounding the company that may hinder its potential for share price growth.
This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.
Cingulate (CING) Analyst Forecast & Price Prediction
Start investing in Cingulate (CING)
Order type
Buy in
Order amount
Est. shares
0 shares